Biocept Inc (BIOC)

0.58
0.01 2.20
NASDAQ : Health Care
Prev Close 0.59
Open 0.60
Day Low/High 0.55 / 0.60
52 Wk Low/High 0.49 / 2.76
Volume 118.97K
Avg Volume 289.10K
Exchange NASDAQ
Shares Outstanding 25.19M
Market Cap 14.36M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Expands Distribution Of Liquid Biopsy Tests To The Philippines

Biocept Expands Distribution Of Liquid Biopsy Tests To The Philippines

Enters into agreement with HarlePhil Ventures, marking the Company's third announced international distribution partnership

Biocept Granted Japanese Patent Covering Microchannel And Antibody Capture

Biocept Granted Japanese Patent Covering Microchannel And Antibody Capture

Strengthens global intellectual property position with 13th issued patent covering the company's proprietary technology for the capture and detection of rare cells from biological fluids

Biocept Comments On Reimbursement Provisions In CMS' Final PAMA Rule

Biocept Comments On Reimbursement Provisions In CMS' Final PAMA Rule

Commends CMS for supporting innovation in diagnostics and transparency on future Medicare pricing

Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test

Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test

New test uses patient's blood sample to profile and monitor for PD-L1 expression, an important biomarker in immuno-oncology treatment decision making

High Sensitivity Of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured In Two Abstracts At ASCO

High Sensitivity Of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured In Two Abstracts At ASCO

Study data further support the clinical utility and validation of Biocept's CTC and ctDNA tests to profile and monitor biomarker status in patients diagnosed with cancer

Biocept Announces Master Services Agreement With Pharma Company To Develop Liquid Biopsy Tests

Biocept Announces Master Services Agreement With Pharma Company To Develop Liquid Biopsy Tests

Continues to execute on 2016 Company priority with second pharma company agreement

Biocept Launches Proprietary Liquid Biopsy Test To Detect RET Fusions In Patients With Lung Cancer

Biocept Launches Proprietary Liquid Biopsy Test To Detect RET Fusions In Patients With Lung Cancer

Detecting RET fusions can identify patients who may benefit from targeted therapy with tyrosine kinase inhibitors

Biocept Expands Intellectual Property Portfolio With 12th Granted Patent On Its Key Liquid Biopsy Technology

Biocept Expands Intellectual Property Portfolio With 12th Granted Patent On Its Key Liquid Biopsy Technology

This sixth U.S. patent covers unique method used for detection of rare cells including circulating tumor cells

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

Biocept Collaborates With MedStar Georgetown University Hospital For Liquid Biopsy Study

Biocept Collaborates With MedStar Georgetown University Hospital For Liquid Biopsy Study

Study focuses on Resistance Mechanisms in Non-Small Cell Lung Cancer; Data Expected to Further Support the Clinical Utility of Biocept's Liquid Biopsy Technology

Biocept Continues International Expansion Through Agreement With Quest Diagnostics Mexico

Biocept Continues International Expansion Through Agreement With Quest Diagnostics Mexico

Biocept's Liquid Biopsy Test that Detects EGFR Mutations Associated with Lung Cancer to be Easily Accessible in Mexico

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept Forms Clinical Advisory Board Of World-Renowned Oncologists

Biocept Forms Clinical Advisory Board Of World-Renowned Oncologists

Key Opinion Leaders to Advise on Expanding Adoption of Biocept's Liquid Biopsy Tests

Biocept To Collaborate On Biopharma Company Clinical Trial By Identifying Biomarkers Found In Cerebral Spinal Fluid For Patients With Lung Cancer That Has Spread To The Brain

Biocept To Collaborate On Biopharma Company Clinical Trial By Identifying Biomarkers Found In Cerebral Spinal Fluid For Patients With Lung Cancer That Has Spread To The Brain

Trial Data Expected to Provide Further Clinical Validation of Biocept's CTC and ctDNA Liquid Biopsy Testing and Platforms for Biomarker Detection in Patients Diagnosed with Non-Small Cell Lung Cancer

Biocept Secures Agreement With FedMed

Biocept Secures Agreement With FedMed

More than 40 million Americans gain access to Biocept's liquid biopsy tests through the FedMed National Provider Network

Biocept To Present At Molecular Medicine Tri-Con 2016

Biocept To Present At Molecular Medicine Tri-Con 2016

Presentation to focus on Biocept's unique, patented technology to capture a broad range of CTCs leading to clinical applications and utility

Biocept Issues Letter To Stockholders

Biocept Issues Letter To Stockholders

Revenue-producing sample volume during 2015 increases by more than 30% each consecutive quarter to greater than 1,800 for the year